Definitive Contract HHSN261201200061C

<p>This is a $200,000.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Bnoat Oncology, a Small Disadvantaged Business and Woman-Owned Small Business. The contract is for the Purification, Reformulation and Pharmacokinetics of Nitrosylcobalamin, a Vitamin B12-based anti-tumor agent, under the Small Business Innovation Research (SBIR) Phase I program. The contract has a completion date of September 30, 2011.</p>

<p>This is a $779,879.76 definitive contract awarded by the National Cancer Institute, a civilian agency, to Cynvenio Biosystems, Inc., a small disadvantaged business. The contract is for research and development in the biomedical basic research domain and has a total small business set aside. The contract was awarded on September 20, 2013 and has a final completion date of September 19, 2015. The contract is a cost-no-fee type with a fixed-price pricing structure.</p>

<p>This is a $299,990.00 firm-fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Evorx Technologies, Inc., a small disadvantaged business. The contract was set aside for small businesses. The award is for an unspecified product or service related to the NCI's mission, with a period of performance ending on February 28, 2017. No additional details about the specific requirements or work to be performed are provided.</p>

<p>This is a $150,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Bioptix Diagnostics, Inc., a for-profit manufacturer. The contract is for Phase I of a Small Business Innovation Research (SBIR) project under Topic 281. The contract has a completion date of June 29, 2011. As an SBIR award, this contract was set aside for small businesses.</p>

This is a federal contract award by the National Cancer Institute, a civilian agency, to Vignet Inc., a minority-owned, woman-owned small business. The contract is for research and development in the medical/biomedical field, with a ceiling value of $1,386,076.38 and a period of performance ending on December 31, 2019. The contract type is a cost-plus-fixed-fee definitive contract, with no set-aside designation. Based on the agency and contract description, this award is likely part of the...

This is a $182,050 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanoivd, Inc., a small disadvantaged, woman-owned business. The contract is for TAS::75 0849::TAS and has a total small business set-aside designation. The period of performance runs from the award date of September 30, 2010 through the ultimate completion date of March 30, 2011. Nanoivd, Inc. is the prime contractor, and no subcontractors are mentioned. The contract...

<p>This is a Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Caerus Discovery, LLC, a Woman-Owned Small Business. The contract is valued at $224,475.00 and has a completion date of June 11, 2015. The contract is for the delivery of a monoclonal antibody targeting cancer stem cells. No set-aside was used for this award. The place of performance is Nokesville, Virginia.</p>

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...

<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>

This is a $1,199,956.00 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanovector Incorporated. The contract is for &quot;OTHER FUNCTIONS TOPIC 267, MULTIFUNCTIONAL THERAPEUTICS USING ENGINEERED PLANT VIRUS NANOPARTICLES&quot; and was set aside for small businesses. The contract has an ultimate completion date of September 27, 2014 and was awarded on September 28, 2012. This contract appears to be part of the NCI's research and development...